ZURICH, June 10 (Reuters) - The following are some of the
main factors expected to affect Swiss stocks on Wednesday:
NOVARTIS NOVN.VX
Novartis AG NOVN.VX said one-year results of its drug
secukinumab show it is effective in treating patients with
ankylosing spondylitis (AS), a debilitating joint condition of
the spine.
For more, click on NOVN.VX
ROCHE ROG.VX
Roche ROG.VX said it received breakthrough therapy
designation from the U.S. health regulator for its Actemra
treatment in systemic sclerosis.
For more, click on ROG.VX
BARRY CALLEBAUT BARN.S
Swiss chocolate maker Barry Callebaut BARN.S said on
Wednesday it is naming Unilever ULVR.L executive Antoine de
Saint-Affrique as its new Chief Executive effective in October,
replacing Juergen Steinemann, who is stepping down in August.
For more, click on BARN.S
BERNER KANTONALBANK BEKN.S
Berner Kantonalbank BEKN.S agreed to pay the United States
nearly $4.62 million under a resolution announced on Tuesday by
the U.S. Justice Department. The bank said in a statement the
penalty will have no impact on its results for the current year
and that it had already made appropriate provisions in 2013.
For more click on BEKN.S
COMPANY STATEMENTS CPR-CH
* The Swiss bourse said it granted an extension to UBS
UBSG.VX in relation to the Swiss bank's delisting of shares
from its entity prior to a share swap into a new company.
UBSG.VX
* Santhera SANN.S said it has discussed its plans to
submit a New Drug Application (NDA) for idebenone to treat
patients with Duchenne Muscular Dystrophy with the US Food and
Drug Administration in a pre-NDA meeting. The Swiss firm said it
and FDA agreed that data presented at the meeting will be
further discussed during a second meeting. SANN.S
* Partners Group PGHN.S said it has raised $700 million
for a multi-asset credit strategy program, Partners Group
Multi-Asset Credit Strategy 2014, the first comingled investment
program to offer investors comprehensive exposure to private
markets debt, incorporating real estate and infrastructure debt
as well as corporate debt. PGHN.S
* Kudelski KUD.S announced a multi-year patent cross
license agreement with Bloomberg Finance L.P. The terms of the
agreement remain confidential, Kudelski said, with Bloomberg
making a one-time payment to the company. KUD.S
* Zueblin ZUBN.S said it will hold a shareholder meeting
on June 30 to propose, among others, a reduction of the share
capital with a simultaneous increase of the share capital.
ZUBN.S
ECONOMY M-CH
Swiss bond auction result due at 0900 GMT
(Reporting by Zurich newsroom)
((+41 58 306 7336)(zurich.newsroom@thomsonreuters.com))